KalVista Pharmaceuticals (KALV) Cash from Operations Growth (1y) (2015 - 2025)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 60.84% |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 85.14% |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -15.72% |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 74.39% |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 3.23% |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 158.60% |
| 10 | KalVista Pharmaceuticals | 1.44 Bn | 1.25 Bn | 56.41 Mn | -35.51% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -35.51% |
| Apr 30, 2025 | -167.22% |
| Oct 31, 2024 | -99.96% |
| Jul 31, 2024 | -50.47% |
| Apr 30, 2024 | 33.27% |
| Jan 31, 2024 | -196.81% |
| Oct 31, 2023 | 3.73% |
| Jul 31, 2023 | -17.54% |
| Apr 30, 2023 | 15.50% |
| Jan 31, 2023 | 33.96% |
| Oct 31, 2022 | -5.37% |
| Jul 31, 2022 | -28.23% |
| Apr 30, 2022 | -142.54% |
| Jan 31, 2022 | -85.41% |
| Oct 31, 2021 | -145.79% |
| Jul 31, 2021 | -394.29% |
| Apr 30, 2021 | 12.47% |
| Jan 31, 2021 | 42.13% |
| Oct 31, 2020 | -1.77% |
| Jul 31, 2020 | 68.18% |
| Apr 30, 2020 | -20.05% |
| Jan 31, 2020 | -20.75% |
| Oct 31, 2019 | 11.06% |
| Jul 31, 2019 | -81.50% |
| Apr 30, 2019 | -76.51% |
| Jan 31, 2019 | -138.47% |
| Oct 31, 2018 | -21.04% |
| Jul 31, 2018 | -39.66% |
| Apr 30, 2018 | -125.48% |
| Jan 31, 2018 | 351.05% |
| Oct 31, 2017 | -73.41% |
| Jul 31, 2017 | 21.33% |
| Mar 31, 2016 | -25.56% |
| Sep 30, 2015 | -64.58% |
| Jun 30, 2015 | -232.35% |
| Mar 31, 2015 | -130.84% |